Erratum: Author Correction: Antibody responses to the RTS,S/AS01_E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique

Lina Sánchez^{1

2}, Marta Vidal¹, Chenjerai Jairoce^{1

3}, Ruth Aguilar¹, Itziar Ubillos¹, Inocencia Cuamba³, Augusto J Nhabomba³, Nana Aba Williams¹, Núria Díez-Padrisa¹, David Cavanagh⁴, Evelina Angov⁵, Ross L Coppel⁶, Deepak Gaur^{7

8}, James G Beeson⁹, Sheetij Dutta⁵, Pedro Aide³, Joseph J Campo^{1

3}, Gemma Moncunill^#^{1

3}, Carlota Dobaño^#^{1

3}

Affiliations

¹ ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.
² UnivLyon, Université Claude Bernard Lyon 1, 69100 Villeurbanne, France.
³ Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
⁴ Institute of Immunology & Infection Research and Centre for Immunity, Infection & Evolution, Ashworth Laboratories, School of Biological Sciences, University of Edinburgh, King's Buildings, Edinburgh, UK.
⁵ U.S. Military Malaria Vaccine Program, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD USA.
⁶ Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Melbourne, VIC Australia.
⁷ Malaria Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.
⁸ Laboratory of Malaria and Vaccine Research, School of Biotechnology, Jawaharlal Nehru University, New Delhi, India.
⁹ Burnet Institute, Melbourne, VIC Australia.

^# Contributed equally.

Published Erratum

Lina Sánchez et al. NPJ Vaccines. 2020.

. 2020 Jul 20:5:63.

doi: 10.1038/s41541-020-00213-3. eCollection 2020.

¹ ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.
² UnivLyon, Université Claude Bernard Lyon 1, 69100 Villeurbanne, France.
³ Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
⁴ Institute of Immunology & Infection Research and Centre for Immunity, Infection & Evolution, Ashworth Laboratories, School of Biological Sciences, University of Edinburgh, King's Buildings, Edinburgh, UK.
⁵ U.S. Military Malaria Vaccine Program, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD USA.
⁶ Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Melbourne, VIC Australia.
⁷ Malaria Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.
⁸ Laboratory of Malaria and Vaccine Research, School of Biotechnology, Jawaharlal Nehru University, New Delhi, India.
⁹ Burnet Institute, Melbourne, VIC Australia.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.1038/s41541-020-0192-7.].

Keywords: Adaptive immunity; Malaria; Vaccines.

Antibody responses to the RTS,S/AS01_E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique.
Sanchez L, Vidal M, Jairoce C, Aguilar R, Ubillos I, Cuamba I, Nhabomba AJ, Williams NA, Díez-Padrisa N, Cavanagh D, Angov E, Coppel RL, Gaur D, Beeson JG, Dutta S, Aide P, Campo JJ, Moncunill G, Dobaño C. Sanchez L, et al. NPJ Vaccines. 2020 Jun 4;5:46. doi: 10.1038/s41541-020-0192-7. eCollection 2020. NPJ Vaccines. 2020. PMID: 32550014 Free PMC article.